UNSPSC 51292906: Homopipramol

This classification denotes an antidepressant agent with the molecular formula C24H31N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 09YNW8E5CT, chemically known as 4-(3-(5h-dibenz(b,f)azepin-5-yl)propyl)hexahydro-1h-1,4-diazepine-1-ethanol but generally known as homopipramol, which bears US NIH Compound Identifier 216247. European Medicines Agency schedules Homopipramol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08052MIG.

UNSPSC 51292906 Homopipramol, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The three most recent opportunities in the source—Seminole County's naloxone and drug deactivation systems purchase, Texas HHS's direct-to-manufacturer prescription program RFI, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals and OTC products RFP—all address broader pharmaceutical supply, drug-disposal systems, and pharmacy benefit management rather than homopipramol specifically. The code shows little relevant recent activity to substantiate active procurement demand for this particular pharmaceutical product at the state or local level.

The issuing bodies across these opportunities span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing vehicles (MMCAP, administered by Minnesota Department of Administration). Geographic activity clusters in Florida, Texas, and the Upper Midwest (Minnesota and Oregon participating in MMCAP). Recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems due July 26, 2023 (1,900 units annually); Texas HHS's RFI for direct-to-manufacturer prescription capabilities, due April 3, 2026; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026. None of these opportunities specifically targets homopipramol procurement, suggesting the code assignment may reflect data-entry error or taxonomy misalignment rather than active demand under this commodity's stated scope.